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OBJECTIVES 
Systemic lupus erythematosus (SLE) is a disease of unknown aetiology in which a wide variety of tissues 
and cells are damaged by deposition of pathogenic auto-antibodies and/or immune complexes. 
It has been observed that the majority of these patients manifest some abnormality of the haematopoietic 
system. Cytopenias affecting one or more cell lines are particularly common, their reported incidences 
varying widely in different published series. The mechanisms underlying these abnormalities have not as 
yet been clearly defined. This is in part due to uncertainty about the role of auto-immunity in their 
pathogenesis, and in further part due to the simultaneous occurrence of various complicating factors that 
include drugs and renal failure. 
To document the incidence of the cytopenias, as well as to define as far as possible the mechanisms 
underlying these abnormalities, haematological studies were conducted on 70 selected SLE patients 
attending Groote Schuur Hospital. A further objective was the presentation of guidelines for the 
management of cytopenias in these patients. 
CHAPTER TWO 
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DEFINITION 
4 
Systemic lupus erythematosus (SLE) is a clinical syndrome of unknown cause or causes characterized by 
inflammation and multisystem involvement. It displays a widely variable presentation and course, being 
subject to multiple remissions and exacerbations in one or more systems. In approximately 30% of cases, 
the disease is induced by known drugs. 
CLASSIFICATION 
SLE has been classified in the group of disorders labeled collagen vascular diseases or connective tissue 
disorders. Although the former is a misnomer, the term applies to a category of distinct illnesses of 
differing aetiology but having similar clinical manifestation that affect connective tissue either primarily or 
secondarily. The syndromes usually included are serum sickness, rheumatoid arthritis, SLE, polyarteritis, 
dermatomyositis, and scleroderma (1). 
A wide variety of clinical and laboratory abnormalities are associated with SLE. Because considerable 
overlap exists with other rheumatic disorders, attempts have been made to classify SLE in a manner that 
would allow for the greatest degree of sensitivity and specificity. The first international classification 
system was devised in Geneva in 1965-1966. Subsequently, the International Reference Centre established 
criteria based on two dozen centres (2). This was superseded by the American Rheumatism Association 
(ARA) preliminary criteria, published in 1971 (3). In 1979 an ARA subcommittee was created to 
re-evaluate these criteria, and in 1982 published revised criteria ( 4). These are the presently accepted 
criteria, and are detailed in Table 2.1. 
GEOGRAPHY,RACEANDSEX 
SLE has a worldwide distribution. Conflicting reports have documented apparent increases in incidence 
and prevalence among certain racial, religious, or geographical groupings. The incidence and prevalence 
of SLE in Jamaica, Uganda, Great Britain, Malaysia, New Zealand, Australia, Iraq, Norway, China, 
Zimbabwe, Finland and Sweden are probably within close ranges of each other (1). Despite some studies 
showing an increased incidence of lupus in black Americans (5,6), socioeconomic factors may be 
operative here. Claims that SLE is rare in black Africans have been recently challenged by Dessein, 
Gledhill and Rossouw (7). In Cape Town, SLE is most frequently encountered in females of mixed 
ancestry (8). 
Ninety percent of cases occur in women, usually of child-bearing age, but children, men, and the elderly 
can be affected (9). After age 50 the preponderance of females is much smaller (1). 
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1982 Revised Criteria for Classification of Systemic Lupus Erythematosus* 
Criterion 
1. Matar rash 
2. Discoid rash 
3. Photosensitivity 
4. Oral ulcers 
5. Arthritis 
6 . Serositis 
7. Renal disorder 
8. Neurologic disorder 
9. Hematologic disorder 
10. Immunologic disorder 
Definition 
Fixed erythema. flat or raised . over the malar eminences . tend-
ing to spare the nasolabial folds 
Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
Skin rash as a result of unusual reaction to sunlight, by patient 
history or physician observation 
Oral or nasopharyngeal ulceration, usually painless. observed by 
a physician 
Nonerosive arthritis involving 2 or more peripheral joints, char-
acterized by tenderness, swelling, or effusion 
a) Pleuritis-convincing history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion 
OR 
b) Pericarditis-documented by ECG or rub or evidence of pericar-
dia! effusion 
a) Persistent proteinuria greater than 0.5 g per day or greater than 
3 + if quantitation not performed 
OR 
b) Cellular casts-may be red cell. hemoglobin. granular, tubular. 
or mixed 
a) Seizures-in the absence of offending drugs or known metabolic 
derangements; e.g., uremia. ketoacidosis, or electrolyte imbal-
ance 
OR 
b) Psychosis-in the absence of offending drugs or known meta-
bolic derangements , e.g .. uremia. ketoacidosis. or electrolyte im-
balance 
a) Hemolytic anemia-with reticulocytosis 
OR 
b) Leukopenia-less than 4,000/mm3 total on 2 or more occasions 
OR 
c) Lymphopenia-less than 1,500/mm 3 on 2 or more occasions 
OR 
d) Thrombocytopenia-less than 100,000/mm 3 in the absence of of-
fending drugs 
a) Positive LE cell preparation 
OR 
b) Anti-DNA : antibody to native DNA in abnormal titer 
OR 
cl Anti-Sm : presence of antibody to Sm nuclear antigen 
OR 
d) False-positive serologic test for syphilis known to be positive for 
at least 6 months and confirmed by Treponema pallidum immo-
bilization or fluorescent treponemal antibody absorption test 
11. Antinuclear antibody An abnormal titer of antinuclear antibody by immunofluores-
cence or an equivalent assay at any point in time and in the ab-
sence of drugs known to be associated with "drug-induced 
lupus" syndrome 
*The proposed classification is based on 11 criteria. For the purpose of identifying patients in clinical 
studies , a person shall be said to have systemic lupus erythematosus if any 4 or more of the 11 criteria are 
present, serially or simultaneously , during any interval of observation. 
Table 2.1. The 1982 revised criteria for the classification of systemic lupus erythematosus. 
Source: Wallace DJ, Dubois EL (1). 
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PATHOGENESIS 
The aetiology of SLE is multifactorial with at least four major components playing a crucial role: genetics, 
viruses, sex hormones and stress. In a given patient, one, two, three, or all four factors may be required for 
the disease to become clinically manifest, with the actual contribution from each factor varying in 
different patients. 
Genetic Predisposition 
This is indicated by a high concordance for clinical disease in monozygotic but not dizygotic twins, and a 
10 percent frequency of patients with more than one affected individual in the family (9). 
Normal individuals who have In..A-B8/DR3 antigens have evidence of immunologic hyperresponsiveness 
as evidenced by studies of humoral and cellular immunity (10,11). In SLE, there is only a weak genetic 
association with In.A DR3 and DR2 (12), suggesting that other genes might also contribute to disease 
susceptibility. A significant proportion of SLE patients possess null alleles for the complement genes 
C4A, C4B and C2, resulting in a complement deficiency. This may cause inefficient clearing of immune 
complexes from the circulation with. deposition in the tissues, leading to inflammatory reactions (13). 
Furthermore, In..A-DR3 is in strong linkage disequilibrium with the C4A and C4B null alleles (14), so 
that it is unclear whether the complement deficiency itself, the In.A gene, or another gene closely linked 
with In.A is responsible for the association. An additional abnormality in these patients is a deficiency of 
erythrocyte CRl (15), which would further diminish host clearance of immune complexes. 
Viruses 
Viruses have been strongly suspected as aetiologic agents, but this is not proven. Every attempt to isolate 
a virus or other agent from lupus patients has failed (16). 
Sex Hormones 
SLE is 10 times more common in females than in males because normal females are more 
immunologically reactive than normal males and therefore more likely to develop autoimmune disorders 
(17). The basis for these observations lies in the ability of sex steroid hormones to modulate immune 
reactivity, with androgens suppressing and oestrogens augmenting antibody responses. Men and women 
with SLE have increased hydroxylation of oestrogen and oestrone to 16-hydroxyoestrone, producing 
prolonged oestrogenic stimulation (18). There is also evidence for decreased total androgens in SLE (19). 
Stress 
The existence of important physiologic connections between the neuroendocrine, classical endocrine and 
immune systems is well established (20). Stress, mood and emotions can act directly or indirectly on all 
three systems. Coupled with a strong biologic predisposition from the other three factors mentioned 
above, a stressful event, through immune or other mechanisms, might be enough to trigger the onset of 
SLE (1). 
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IMMUNOLOGY 
Patients with SLE have numerous immune abnormalities. Among the earliest manifestations of active 
SLE are hypergammaglobulinaemia and impaired T-cell function. When the disease is quiescent, many of 
the immune defects return toward normal. Therefore, they may not be the cause but rather the result of 
other factors which underlie disease. 
B-cell abnormalities 
Central to the development of SLE is the overproduction of antibodies reactive with cell membrane 
molecules, cytoplasmic proteins, and nuclear determinants (most notably DNA). These autoantibodies 
are responsible, in whole or in part, for a variety of pathogenic processes, including abnormalities in 
T-cell function, glomerulonephritis, and vasculitis. In active lupus, patients have 
hypergammaglobulinaemia (21) and increased numbers of activated B cells. (22,23). There is a large 
increase in numbers of immunoglobulin-secreting cells in patients with active disease (22,23), and a strong 
correlation between this increase and disease activity (22). Although serum immunoglobulin levels rise 
during periods of active disease, the concentration of certain antibodies (such as anti-DNA) may rise at a 
disproportionately rapid rate in some patients. Thus autoantibody production in SLE may be induced and 
perpetuated by immunization with autoantigens or antigens cross-reactive with self. Furthermore, it is 
possible that hypergammaglobulinaemia results directly from increased autoantibody production. Thus it 
is postulated that the B-cell hyper-proliferation results from their exposure to both self and foreign 
antigens in the context of a polyclonal activator (24). 
The nature of autoantibodies 
The precise nature of autoantibody-secreting B-cells in SLE is uncertain. There is also considerable 
controversy concerning the nature of autoantibodies themselves. While similar to conventional antibodies 
in general structure, it has nevertheless been proposed that autoantibodies are unusually cross-reactive. 
Thus, the reactivity of lupus serum with a variety of different autoantigens has been attributed to the 
presence of autoantibodies capable of binding to a wide variety of self-determinants (25,26). The precise 
epitopes recognized by such antibodies have not been determined. 
T -cell function 
During active disease, T-cell function is much impaired. This includes impaired T-cell both helper and 
suppressor function, impaired IL-2 production, impaired T-cell-mediated cytotoxicity, and impaired skin 
test responses to standard challenge. These T-cell defects may be secondary to disease rather than 
primary defects, and may serve as mechanisms for perpetuation of disease processes. Thus, they may not 
contribute importantly to induction of disease. After the active disease recedes, T-cell function begins to 
return toward normal (24). 
Immune regulation 
Abnormal immune regulation appears to play a critical role in the pathogenesis and perpetuation of SLE. 
Available data suggests that polyclonal immune activity precedes impaired T-cell responses to antigens 
and mitogens. It is only after such stimulatory activities have led to substantial immune hyperactivity that 
T-cell functions are reduced. That sequence suggests that many of the impaired T-cell responses 
observed in lupus are secondary to the immune hyperactivity and not the cause of it. The secondary 
immune defects most likely result from hypergammaglobulinaemia, increased prostaglandin production 
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secondary to immune activation, and imbalance between interferon and IL-4 production (increased) and 
IL-2 production (decreased) (24). 
SEROLOGY 
Autoantibodies 
The disturbance in immunologic homeostasis in SLE is manifested primarily by the presence of many 
types of autoantibodies in the serum, as listed in Table 2.2. 
AulolntlbodlN In patients with SL£ 
Antinuclear antibodies 
Anti-DNA 
Anti-Sm 
Anti-RNP 
Anti-Ro (SSA) 
Anti-La (SSB) 
AnrihilloDe 
AnticanliolipiD 
ADlia ydrocyte 
Anciplalelct 
.Alltilympbocyt 
Antincuronal 
Incidence , ~ 
95 
70 
30 
40 
30 
10 
70 
50 
60 
70 
60 
Antigen 
dctcc:ted 
Multiple nuclear and cyu>-
plasmic antigens 
DNA 
Polypeptides complexed to 6 
species of small nuclear 
RNA 
Polypeptides complexed to 
UiftNA 
RNA polymerase 
Prolein complexed to RNAs 
Hisloncs 
Ery1bnxyte surf-.e antigens 
Plalclct surf-.e 
Lymphocyte surf-.e antis-
Neuronal surf-.e antis-
Human cell line ~ AR more sensitive 1111111 Slandard murine 
tissues. A ,q,eaaedly oeplivc lest oa bodl makes SLE diqnolil 
lllllikcly. Mwtiple antibodies AR detected . 
Anti-dsDNA is relatively discase-speci6c; anti-ssDNA is not. Associm1 
will! nephritis md clinical activity . 
Speci6c for SLE. 
High tit.er seen in syndromes with featw'CS of polymy05itis, sclerodc:rma. 
lupus and mixed connective tissue disease . If present in SLE witboul 
anti-DNA, risk for nephritis is low. 
Associaled wi~'s syndrome, DR3 baploeype , subacute cuta-
- lupus, - deficiencies, ANA-oeplive lupua, lupus ill 
tbc elderly, neoaalal lupus, congenital heart bloct in infants. Can 
- nephritis. 
When ISIOCialed will! lllli-Ro, risk for nephritis is low. 
MIR &equeDI in dru1-induced LE (95 pat:elll) 1111111 in spoolllleOIII 
SLE. 
lncreues lilt for VCDOUS or arterial tbromboua md for spoatancous 
abortiml. Allocialed widl poloaged PTr (lupis llllicoagulant) aid 
falle-politivc VDRL. 
A amall proportioa of tbcsc patients develop owrt bcmolysis. 
Allocialed with tbrombocylopeni. 
Plobably IUOcialed will! leukopeni.a 1111d abnormal T-cell function , 
ID CSF, bisb Ig(i titers c:onelate will! diffuse but not focal CNS lupus. 
Table 2.2 Autoantibodics in patients with systemic lupus ei:ythematosus. 
Source: Harrison's Principles of Internal Medicine (9). 
Those of greatest clinical significance are directed against nuclear antigens, namely antinuclear 
antibodies (ANA). These are invariably present in SLE, and can be detected in as many as 99% of 
patients with this disease. However ANA can be demonstrated in 5% of normal individuals, and 
occasionally in certain diseases not considered to be autoimmune, for example infectious mononucleosis 
and chronic active hepatitis. 
ANA immunologic specificities can be divided into three general categories: antibody directed against 
DNA, those directed against histone (a family of basic nuclear proteins), and those against nonhistone 
nuclear antigens (1). 
Anti-DNA antibodies can be classified according to their reactivities with double-stranded or 
single-stranded DNA. Clinically, antibodies to double-stranded DNA are highly specific for SLE and 
rarely seen in a significant titer in other systemic rheumatic diseases. The prevalence of these antibodies 
in SLE depends mainly on the disease activity and on the organ systems involved when the antibodies are 
measured. They are increased during phases of increased disease activity and are decreased when 
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patients are in remission. Thus, quantitation of antibody to double-stranded DNA is recommended as a 
useful tool in assessing disease activity. Antibodies to single-stranded DNA are commonly found in SLE, 
but are frequently observed in other systemic rheumatic diseases, and occasionally in normal individuals. 
Thus this antibody is usually not a useful diagnostic marker (1). 
Autoantibodies to histones have multiple specificities and are reactive with all of the five major classes of 
histones: HI, H2A, H2B, H3 and H4. A close association exists between antihistone antibodies and 
drug-induced LE, particularly in patients taking procainamide. However, these antibodies have been 
reported in 80% of patients with idiopathic SLE (1). 
The third major class of ANA in SLE is characterized by reactivities with soluble nonhistone nuclear 
protein and RNA-protein complexes. Antibody to Sm was the first such antibody reported, and it is 
present almost exclusively in SLE. It is, in fact, considered a diagnostic marker for the disease. Although 
it is present in only 30% of patients with SLE, it is highly specific in that it has not been detected in 
normal sera or in the sera of patients with other systemic rheumatic diseases. Antibodies to Ul-RNP 
(nuclear RNP) antigen are found in high titer in patients with mixed connective tissue disease, but also in 
SLE patients and those with a variety of systemic rheumatic diseases. ENA ( originally extractable nuclear 
antigen) complex refers to the association of Ul-RNP and Sm in complexes (1). 
Two other types of ANA also included in this group occur in patients with SLE and patients with 
Sjogren's syndrome - anti-SS-A/Ro and anti-SS-B/La antibodies. The former is present in 30-40% of 
patients with SLE, approximately 70% of patients with Sjogren's syndrome, and about 20% of patients 
with rheumatoid arthritis. Several clinical associations exist between the presence of anti-SS-A/Ro and 
certain subtypes of SLE, for example subacute cutaneous lupus and neonatal lupus. Antibody to SS-B/La 
is detected in the sera of SLE patients less frequently than anti-SS-A/Ro, of the order of 15%. However, 
it can be detected in 45-60% of patients with Sjogren's syndrome. Except for the overlapping presence of 
Sjogren's syndrome in patients with SLE, no distinguishing clinical features appear to be associated with 
the presence of anti-SS-B/La (1). 
There are a number of lesser important antibodies found in some SLE patients, for example antibodies to 
proliferating cell nuclear antigen (PCNA), MA and Ki antigen and to high mobility group (HMG) 
proteins (1). 
Other serologic abnormalities found in SLE include the presence of rheumatoid factors in about 30%, 
anti-neuron antibodies in patients with neuropsychiatric manifestations, and anti-erythrocyte, 
anti-leucocyte and anti-platelet antibodies. Anticardiolipin antibodies (about 60% of patients, but not 
specific for SLE) belong to a heterogeneous group of autoantibodies found in SLE sera reactive with 
phospholipids. Other antiphospholipid antibodies include lupus anticoagulant and antibodies responsible 
for a biologic false positive VDRL test. High serum titer of anticardiolipin antibodies in SLE is 
significantly associated with venous or arterial thrombosis, thrombocytopenia, and/or spontaneous 
multiple abortions (1). 
Immune Complexes 
Considerable evidence shows that much of the pathology in patients with SLE can be attributed to the 
presence of immune complexes. These consist of combinations of antigens and antibodies and may either 
form in the circulation and later deposit in tissues, or arise in situ. They do not appear to cause tissue 
inflammation directly, but rather through activation of the complement system. This causes release of 
various mediators, promotes cell interaction, and ultimately results in inflammation. In SLE, there is 
defective reticuloendothelial clearance of these immune complexes due to a number of factors, some 
inherited, and some acquired. Measurement of immune complexes or evaluation of the complement 
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system (which can serve as an indirect measure of the presence of immune complexes) often correlates 
with the clinical aspects of SLE ( 1). 
Complement 
Complement deficiencies in SLE patients may be inherited or acquired, and involve virtually any of the 
complement components. Assessment of the complement system is by measurement of total haemolytic 
complement (CH50) or haemolytic measurement of individual components, with C3 and C4 being 
estimated most frequently. Low levels of complement usually reflect disease activity, especially in patients 
with nephritis, with CH50 being the most sensitive measure of complement activation. Associations have 
been noted between low levels of individual components and various facets of SLE (1). 
CLINICAL SPECTRUM 
Clinical manifestations of the disease are determined by which antibody subpopulations and immune 
complexes are present in the patient's repertoire, which organs, cells, or cell products are their targets, 
and which patients have the ability to correct these abnormalities. 
At its onset, SLE may involve only one organ system, with additional manifestations occurring later, or 
may be multi-systemic (9). The relative incidences of the commonest clinical manifestations are shown in 
Figure 2.1. 
ARTHRITIS AND ARTHRALGIA I 91 .6 
FEVER 183.6 
L . E. CELLS 175.7 
SKIN CHANGES 171.5 
ADENOPATHY 158.6 
ANEMIA (<II GMS . ) I 56.5 
ANOREXIA. NAUSEA VOMIT. I 53.2 
DYSPROTE I NEM I A 153.0 
MYALGIA 148.2 
RENAL CHANGES 146.1 
PLEURITIS 145.0 
LEUKOPENIA 142.6 
PERICARDITIS I 30.5 
PLEURAL EFF. I 30.3 
C.N. S. 125.5 
I I I I I I I I I 
0 10 20 30 40 50 60 70 80 90 100 
CUMULATIVE PERCENT INCIDENCE 
Fig 2.1 Cumulative percentage incidence of the commonest clinical manifestations of 520 cases of SLB. 
Source: Wallace DJ, Dubois EL (1). 
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Disease severity varies from mild and intermittent to persistent and ultimately fatal. Most patients 
experience exacerbations interspersed with periods of relative quiescence, with fewer than 10 percent 
having long-lasting symptom-free remissions. 
Systemic symptoms are usually prominent and include fatigue, malaise, fever, anorexia, weight loss, and 
nausea (9). 
Musculoskeletal 
Almost all SLE patients experience arthralgias and myalgias; most develop arthritis. Pain is often out of 
proportion to physical findings, which include symmetric fusiform swelling of joints (most frequently 
proximal interphalangeal and metacarpophalangeal joints of the hands, wrists and knees), diffuse 
puffiness of hands and feet, and tenosynovitis:' Joint deformities are unusual. Erosions are rare, but 
subcutaneous nodules over the elbows and fingers may occur. Myopathy can be inflammatory and related 
to active disease, or iatrogenically drug induced. Ischaemic necrosis of bone is a common cause of hip 
and shoulder pain (9). 
Cutaneous 
The malar or butterfly rash is a fixed erythematous eruption, flat or raised, over the cheeks and bridge of 
the nose, often involving the chin and ears. A more diffuse maculopapular rash, predominant in 
sun-exposed areas, is also common, and usually indicates disease flare-up. Loss of scalp hair is usually 
patchy but can be extensive. V asculitic skin lesions include subcutaneous nodules, ulcers ( usually on the 
legs), purpura, and infarcts of skin or digits. Discoid lesions occur in some patients with SLE and can be 
disfiguring. They are circular with an erythematous rim, raised, and scaly, with follicular plugging and 
telangiectasia. Central scarring produces depigmentation and permanent loss of appendages. They occur 
over the scalp, external ears, face and sun-exposed areas of the arms, back and chest. Only 5 percent of 
individuals with discoid LE progress to SLE; however 20 percent of SLE patients have DLE lesions. Less 
frequent SLE skin lesions include urticaria, periorbital oedema, bullae, erythema multiforme, 
lichen-planus-like lesions, and panniculitis or lupus profundus. 
Patients with subacute cutaneous lupus (SCLE) are a distinct subset with recurring extensive skin lesions. 
Arthritis and fatigue are frequent; central nervous system and renal involvement are rare. Some are ANA 
negative, but the majority have antibodies to Ro (SS-A) or to single-stranded DNA and carry the 
HLA-DR3 phenotype. The skin lesions are photosensitive polycyclic annular or papulosquamous 
psoriasiform over the arm, trunk and face; they become hypopigmented but not scarred. 
Mucous membrane lesions are usually small, shallow, painless ulcers in the mouth (usually over the 
palate) and nose (9). 
Renal Manifestations 
Although almost all SLE patients have deposits of immunoglobulin in glomeruli, only one-half have 
clinical nephritis, defined by persistent proteinuria. At presentation, most patients are asymptomatic 
(unless already uraemic), except for· those with oedema of the nephrotic syndrome. Urinalysis shows 
haematuria, cylindruria, and proteinuria. Most patients with mesangial or mild focal glomerulonephritis 
do not develop deterioration of renal function. In those with more severe, active, or chronic lesions, renal 
failure is a major cause of death. Renal biopsy is an important investigation to aid subsequent therapeutic 
decisions, with modalities including glucocorticoid and immunosuppressive therapy, dialysis and renal 
transplantation (9). 
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Nervous System 
Any region of the brain can be involved in SLE, as can the meninges, spinal cord, and cranial and 
peripheral nerves. Central nervous system events may be isolated, single, or multiple, but usually occur in 
the setting of active disease in other systems. Mild mental dysfunction is the most frequent manifestation. 
Seizures are common and may be grand mal, petit mal, or focal. Other manifestations include psychosis, 
organic brain syndromes, headache (including migraine), focal infarcts with resultant deficits, 
extrapyramidal disorders, cerebellar dysfunction, hypothalamic dysfunction with inappropriate ADH 
secretion, pseudotumour cerebri, subarachnoid haemorrhage, aseptic meningitis, transverse myelitis with 
paraplegia or quadriplegia, optic neuritis, cranial nerve palsies, and peripheral sensorimotor neuropathy 
resulting either in mononeuritis multiplex or glove-and-stocking deficit. Depression and anxiety are 
frequent. Neurologic problems usually improve (with the exception of deficits related to infarcts) with 
therapy and/or time, but recurrences are common (9). 
Vascular 
Thrombosis in capillaries, in small vessels, and in medium-sized veins and arteries can be a major 
problem. Although vasculitis may play a role, there is increasing evidence that anticardiolipin antibodies 
may initiate clotting. In addition, degenerative vascular changes associated with years of immune-complex 
deposition in vessel walls may predispose to symptomatic coronary artery disease in relatively young 
individuals with SLE (9). 
Cardiopulmonary 
Pericardia! pain is the most frequent symptom of cardiac lupus; pericardia! effusions also occur. 
Myocarditis can cause arrhythmias and/or cardiac failure. Endocarditis of the Libman-Sacks verrucous 
type, a diagnosis made at autopsy, is usually not clinically significant; however it can cause aortic or mitral 
regurgitation. Rarely myocardial infarcts result from vasculitis of the coronary arteries. 
Pleurisy and pleural effusions are common manifestations of SLE. Lupus pneumonitis causes recurrent 
episodes of fever, dyspnoea and cough; x-rays show infiltrates and/or areas of platelike atelectasis. 
Interstitial pneumonitis leading to fibrosis occurs in a small proportion of patients. Occasionally, patients 
may develop pulmonary hypertension. Infrequent but often fatal pulmonary manifestations include adult 
respiratory distress syndrome (ARDS) and massive intraalveolar haemorrhage (9). 
(;astrointestinal 
Nonspecific gastrointestinal symptoms are common, but vasculitis of the intestine is the most dangerous 
manifestation. It causes acute or subacute cramping pain, vomiting and diarrhoea, and leads to intestinal 
perforation and death in almost one-half of the affected patients. Vasculitis is usually present 
simultaneously in other systems. Another gastrointestinal manifestation of SLE is a pseudo-obstruction 
picture in which patients present with acute cramping abdominal pain. Acute pancreatitis may occur and 
can be severe; it may result from steroid therapy or from active SLE. Elevated serum levels of liver 
enzymes, especially transaminases, are common in patients with active SLE, but are not associated with 
significant hepatic damage; they return to normal as the disease is treated (9). 
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Ocular 
The most important ocular manifestation of SLE is retinal vasculitis with infarcts; blindness can develop 
over a period of days. Other ocular abnormalities include conjunctivitis, episcleritis, and optic neuritis. 
The sicca syndrome is frequent (9). 
Drug-induced lupus 
Several drugs can cause a syndrome resembling SLE in individuals without any obvious predisposition to 
the disease. The most common offender is procainamide, which induces ANA in 50-75 percent of 
individuals within a few months; 20 percent of patients receiving the drug develop clinical drug-induced 
LE. Hydralazine induces ANA in 25-30 percent of individuals, and lupus-like symptoms in 10 percent. 
Both procainamide and hydralazine-induced lupus occur more commonly in women, are uncommon in 
blacks, and are more likely to occur in individuals who acetylate the drug slowly; this is especially true for 
hydralazine. The clinical syndrome consists of polyarthralgias and systemic symptoms in most patients. 
Polyarthritis occurs in 25-50 percent, and pleuropericarditis in 30 percent, of patients with hydralazine-
and 50 percent of patients with procainamide-induced lupus. Other manifestations typical of idiopathic 
SLE are unusual, including nephritis and CNS involvement. All patients with drug-induced lupus are 
ANA-positive; most have antibodies to histones. Antibodies to double-stranded DNA and 
hypocomplementaemia are rarely present, which is helpful in distinguishing drug-induced from idiopathic 
lupus. Anaemia, leucopenia, lupus anticoagulant, thrombocytopenia, cryoglobulins, rheumatoid factors, 
false-positive VDRL and positive direct Coombs' tests can occur. 
The initial therapeutic approach should be discontinuance of the suspect drug; most patients improve in 
days or a few weeks. In patients with severe symptoms, a short course (2-10 weeks) of steroids is 
indicated. Clinical symptoms rarely persist more than 6 months, but ANA may remain positive for years. 
Other drugs which infrequently induce lupus-like illnesses include isoniazid, chlorpromazine, 
penicillamine and methyldopa. Most lupus-inducing drugs can be used safely in patients with idiopathic 
lupus if there are no suitable alternatives (9). 
Prognosis 
The overall survival in patients with SLE is approximately 71 percent over 10 years. Patients with severe 
involvement of the brain, lungs, heart, or kidney have the worst outcomes in terms of survival and 
disability. Infections and renal failure are the leading causes of death (9). 
TREATMENT 
Lupus is a chronic disease that often has a relapsing course. The primary therapeutic strategy, therefore, 
is to achieve and maintain adequate suppression of the disease without incurring unacceptable drug 
side-effects. 
Salicylates are useful in treating fever, fatigue, joint pain and inflammation and serositis. They can be used 
as an adjunct to corticosteroids or immunosuppressive agents in patients with internal organ involvement. 
Nonsteroidal anti-inflammatory drugs (NSAID's) are used as substitutes for salicylates in treating fever, 
arthralgia and serositis, or they may be used synergistically with salicylates. However, some NSAID 
toxicities are especially frequent in SLE patients, including hepatitis, aseptic meningitis and renal 
impairment. 
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Tlie dermitides of SLE, including discoid LE, and occasionally lupus arthritis, may respond to 
antimalarials. Side effects include retinal toxicity, rash, myopathy and neuropathy. Other therapies for 
skin rash include use of prophylactic sunscreens and topical corticosteroids (9). 
Some disease manifestations require the use of systemic corticosteroids for effective management. 
Autoimmune haematologic manifestations, including anaemia and thrombocytopenia, pulmonary 
parenchymal disease, lupus nephritis and organic central nervous system disease are usually treated first 
with corticosteroids. In adult patients, high dose glucocorticoids approximately equivalent to prednisone 
lmglkg/day are given for severe disease manifestations. This dose is tapered as disease activity is 
controlled. Some acutely ill patients, including those with nephritis, are treated with a short course of high 
dose intravenous pulse methylprednisolone (27). The range of adverse reactions experienced with 
corticosteroids is broad and includes suppression of the hypothalamic-pituitary axis, hypertension, 
increased susceptibility to infection, glucose intolerance, osteoporosis and psychosis. 
Failure to control severe systemic manifestations with corticosteroids requires the introduction of 
immunosuppressive agents. These drugs may also be used for their steroid-sparing properties or when 
intolerable corticosteroid toxicity occurs. 
The immunosuppressive drug.s most commonly used in SLE are the alkylating agents cyclophosphamide, 
chlorambucil and mechlorethamine (nitrogen mustard), and the antimetabolite azathioprine. The 
antimetabolite methotrexate has been used sparingly. 
Cyclophosphamide has been the most extensively studied of the alkylating agents in SLE. Its immunologic 
effects include depletion of B-cells at low doses, CD8 T-cells (T8, suppressor/cytotoxic cells) at slightly 
higher doses, and CD4 T-cells (T4, helper/inducer cells) at high doses. It has been widely used in the 
treatment of lupus nephritis. Although there have been no controlled trials on the use of 
cyclophosphamide in the treatment of life-threatening and/or active major organ disease except for the 
kidney, there are many reports that indicate a role for its use in these settings, which include 
complications involving the lungs, nervous system and haematologic system (28). Both daily oral and 
bolus intravenous regimes have been used. The most important toxicities in the doses used for treatment 
of rheumatic diseases are major infection, gonadal failure, bladder toxicity and malignancy. Minor 
toxicities include nausea and vomiting and alopecia. 
Azathioprine, whose major immunosuppressive effects are probably mediated by a preferential reduction 
of natural killer cells, may be useful as a steroid-sparing agent in some patients. More specifically, this 
drug may be effective in the treatment of some patients with antimalarial-resistant discoid lupus, and a 
subset of patients with mild to moderate proliferative glomerulonephritis. Azathioprine should probably 
not be the first immunosuppressive drug used for life-threatening disease or active pulmonary, 
haematologic, or central nervous system disease (28). There are few major side effects associated with 
this drug as compared with cyclophosphamide. They include major infection, leucopenia, rarely 
hepatotoxicity and malignancy. 
Chlorambucil has been used to treat lupus nephritis, but is less effective than cyclophosphamide. It may 
have a place in steroid-resistant nephrotic syndrome (29). 
Nitrogen mustard is used with some success in the treatment of renal lupus. 
Preliminary small scale studies of Cyclosporin A, either as a sole agent or in combination with steroids, 
suggest that a subset of severely affected patients may benefit from this drug (30). However, definitive 
evaluation awaits reports of further large scale trials. Side effects are significant and include 
nephrotoxicity, hypertension, hyperkalaemia, hyperuricaemia and hypertrichosis. 
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HAEMATOLOGIC MANIFESTATIONS 
THE CYTOPENIAS 
Haematologic abnormalities occur in almost every patient with SLE, and may be presenting 
manifestations of the disease. Amongst these abnormalities, the cytopenias are particularly common. 
As the focus of this study has been the investigation of cytopenias in SLE, aspects relating to anaemia, 
leucopenia and thrombocytopenia will be covered in depth in this literature review. 
Anaemia 
The commonest haematologic abnormality is anaemia, defined as a haemoglobin level below 110g/L, with 
a reported incidence varying from 38-98% in different series (31,32,33,34). The patients in these series 
were not stratified into treated and untreated groups, nor was it specified at what stage of the disease the 
blood specimens were taken. 
The causes of anaemia are multiple, and both non-immune and immune mechanisms have been 
incriminated (35). Mechanisms are more logically discussed under these two broad groups, rather than 
adopting a physiological approach. 
Anaemia - non-immune mechanisms 
These will be dealt with first, and they include mainly anaemia of chronic disease, iron deficiency, renal 
disease and drugs. 
Anaemic SLE patients most commonly have the anaemia of chronic disease (ACD) (35). It is usually of 
moderate severity, with the haemoglobin rarely falling below 80g/l unless additional factors are present 
(36). Most often, ACD takes the form of a normochromic, normocytic anaemia, but is not infrequently 
hypochromic, and sometimes microcytic. The reticulocyte count is normal, being low for the degree of 
anaemia. The bone marrow shows no specific diagnostic features. Iron stores are normal but the 
percentage of sideroblasts is reduced, suggesting a failure of iron incorporation. The abnormality in iron 
metabolism can be established by finding subnormal values for serum iron concentration and transferrin 
saturation in association with evidence of normal or increased iron stores. Serum ferritin concentration 
usually is increased in ACD, a finding that is often the most convenient means of distinguishing it from 
iron deficiency. Decreased serum transferrin levels are found frequently, but this is neither sensitive nor 
specific enough to be useful in excluding iron deficiency. Ferrokinetic abnormalities include a rapid 
disappearance of Fe from the plasma and a subsequent fast uptake in the macrophage/monocyte system 
(37). 
A number of other biochemical changes occur in association with the anaemia of chronic disease. Most of 
these are manifestations of the acute phase response. New proteins appear in plasma, including 
C-reactive protein and amyloid A protein. Synthesis of other proteins is considerably augmented, 
amongst which are fibrinogen, caeruloplasmin and haptoglobin. The levels of certain other plasma 
proteins, for example albumin and transferrin are reduced in plasma (37). 
Several factors have been implicated in the pathogenesis of ACD, with varying contributions in different 
disease states. 
Many of the findings can be accounted for by release of a monokine interleukin-! (ll.rl), also known as 
leucocyte endogenous mediator or endogenous pyrogen. This is released from activated monocytes, with 
bacterial endotoxins, certain lymphokines and phagocytic challenges being among the factors stimulating 
• 
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its biosynthesis. IL-1 induces fever, leucocytosis, and a variety of biochemical changes, including 
hypoferraemia and alterations in plasma protein synthesis, collectively known as the acute phase 
response. It is proposed that ACD results from the long-term elaboration of IL-1 and that release of this 
substance is the common pathogenetic factor found in the illnesses that are associated with ACD (37). 
The hypoferraemia is probably caused by defective release of iron from cells - particularly from 
macrophages, but also from hepatocytes and intestinal epithelium. This may be due to liberation of 
lactoferrin from neutrophils, which could either remove iron from transferrin, or compete with transferrin 
for the iron released by macrophages. This iron is then returned to the macrophage, where it becomes 
incorporated into stores (38). A second mechanism which may contribute to the hypoferraemia is 
induction of apoferritin synthesis by inflammation. This would bind a larger-than-normal proportion of 
the iron entering the cell, effectively diverting the metal from the rapid-release pathway (39). 
Erythrokinetic studies in ACD have detected a modest reduction in erythrocyte survival without an 
adequate compensatory increase in the rate of red cell production ( 40,41,42,43). The reduced erythrocyte 
survival is probably related to an increase in phagocytic activity by activated macrophages (43). 
In patients with ACD, levels of erythropoietin are inappropriately low for the degree of anaemia 
( 44,45,46). However, the fact that erythropoiesis in ACD can increase when stimulated by hypoxia 
( 47,48), indicates that the erythropoietin secreting mechanism retains the capacity to respond to this 
physiological stimulus. The response, however, appears to be blunted (49). 
The relative contributions of these factors to the pathophysiology of ACD vary in different disease states. 
In the collagen disease group, most studies have been conducted on rheumatoid arthritis patients, but 
their applicability to SLE has not been tested. 
Occult gastrointestinal blood loss possibly on the basis of vasculitis or anti-inflammatory or steroid drug 
ingestion, may result in iron deficiency anaemia, while uraemic patients have anaemia of chronic disease 
with superimposed erythropoietin deficiency. 
Aplastic anaemia may occur in SLE secondary to the use of nitrogen mustard derivatives, antimalarials, 
or other agents such as chloramphenicol (1). 
A few cases of sideroblastic anaemia in SLE have been reported (50,51), and there have been several 
isolated cases of concurrent SLE and sickle cell anaemia (52,53,54,55,56,57). Pure red cell aplasia has 
. been seen in SLE (58,58,60). These are all rare occurrences and contribute only very minimally to the 
causation of-anaemia. 
Anaemia - immune mechanisms 
These include autoimmune haemolytic anaemia and the occurrence of humoral inhibitors of 
erythropoiesis. 
Autoimmune haemolytic anaemias occur with some frequency in SLE, and may predate the appearance 
of diagnosable SLE ( 61,62). The anaemia may be severe, with haemoglobin values below 70g/L (31,32). 
Immunoglobulin, complement, or both, may be found on the surface of red cells in between 18% and 65% 
of patients; however, fewer than 10 percent of patients manifest autoimmune haemolytic anaemia during 
the course of their illness (32,61,63,64). Thus a positive direct Coombs' test in the absence of haemolysis 
should be regarded as one of the multiple abnormal serologic findings in SLE, which in part is a reflection 
of the hyperreactivity of these patients to auto-and hetero-antigens. Autoantibodies to red cells in SLE 
patients are warm antibodies, most commonly belonging to the IgG class, with IgG 1 being the 
predominant subclass. 
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The Coombs' test pattern of reactivity in these patients is usually either Type II, involving both 
immunoglobulin and complement components on the red cell surface, or Type ill, in which red cells are 
coated with complement components alone (65,66,67). The specificity of warm antibodies in SLE is not 
completely known; however, antibody eluted from Coombs' test-positive SLE red cells usually shows no 
known Rh specificity (68). These antibodies often show a strong reaction with Rh null cells (69), thus 
suggesting that the specificity of the immunoglobulin is directed against (a) non-Rh determinants on the 
red cells (70,71). 
A few cases of SLE patients with haemolytic anaemia associated with cold agglutinins have been reported 
(61,64,72,73). However, the Coombs' test in these patients has been described as variable, and most have 
had low titer cold agglutinins. Thus a confirmed association between SLE haemolytic anaemia and cold 
agglutinins as the cause of haemolysis is tenuous (73) . 
Addition of large amounts of erythropoietin to bone marrow cultured in vitro results in the formation of 
committed stem cell colonies, namely BFU-E, or burst forming unit-erythroid. BFU-E's are primitive 
erythroid elements that synthesize embryonal haemoglobin and are unable to differentiate to the 
anucleate mature red cell stage. If grown in cultures to which homologous serum enriched with 
erythropoietin has been added, the BFU-E's mature into CFU-E's, which are colony forming 
unit-erythroid. These then produce normal anucleate red cells containing adult haemoglobin. 
A number of examples of humoral inhibitors of erythropoiesis have been found in SLE patients 
(74,75,76,77,78,79). Five anaemic patients were studied by Kallen et al (75); their sera suppressed CFU-E 
growth of normal human bone marrow and all were steroid responsive. Dainialc et al (76) demonstrated 
that serums from 7 severely anaemic patients with SLE contained a factor which inhibited both BFU-E 
and CFU-E proliferation and/or differentiation with both autologous and allogeneic bone marrow in 
vitro. This inhibitor had immunoglobulin properties and was removed by plasmapheresis or steroids. 
Meyer et al (77) suggested that a circulating autoantibody in an SLE patient causing autoimmune 
haemolytic anaemia could also influence the proliferation or maturation of erythroid progenitor cells. 
There may be a role played by T-cell mediated suppression of erythroid progenitor cells (78), or by an 
IgG complement-dependant antibody (79). 
Treatment 
The anaemia of chronic disease in SLE is rarely life-threatening, and treatment should be directed at the 
underlying disease process. Modest doses of corticosteroids are frequently efficacious in the treatment of 
the systemic manifestations of the disease, and thus secondarily, the associated anaemia. There is no 
response to oral iron therapy (36), unless concomitant absolute deficiency exists (80). In experimental 
animals, the anaemia can be corrected by giving erythropoietin (47,48). The role of replacement therapy 
with this recombinant hormone in correcting the anaemia and improving the quality of life in patients 
with SLE remains to be determined. 
The first modality of treatment for SLE acquired haemolytic anaemia is corticosteroids at a dose of 
1-1.5mg/kg'day. Approximately 75% of patients are expected to respond (81,82). Splenectomy is the 
second option in patients unresponsive to corticosteroids or in whom unacceptably high doses are 
required to suppress disease activity. However, this procedure rarely produces any long-term favourable 
results in the majority of instances of SLE-induced haemolytic anaemia (1). Refractory cases of immune 
haemolytic anaemia may respond to immunosuppressive therapy, and uncontrolled trials have claimed 
that these agents are valuable in this setting (81,82,83,84). The drugs most frequently used have been 
azathioprine and cyclophosphamide. Their use should be limited to resistant disease, as side effects, as 
discussed above, may be serious, particularly with long term therapy. 
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Early studies evaluating the effectiveness of Cyclosporin-A in autoimmune diseases suggest that this agent 
may have a role in treating refractory immune cytopenias, including haemolytic anaemia (30). 
Leucopenia 
Leucopenia, defined as a white cell count below 4x109 /L, is reported to occur in between 35-80% of SLE 
patients ( 4,31,33,34). This may be the result of a depression in circulating granulocytes or lymphocytes or 
both; however the magnitude of the decrease in granulocytes is usually much greater than that of 
lymphocytes (72). 
A number of mechanisms for the granulocytopenia have been suggested, but convincing proof is lacking. 
Those incriminated here include decreased mobilization and drugs, accounting for the non-immune 
group, and immune peripheral destruction and central humoral inhibition. 
Leucopenia . non-immune mechanisms 
Investigation of bone marrow granulocyte reserves may be performed by intramuscular injection of 
etiocholanolone, a naturally occurring hormone metabolite which is a potent stimulus for the mobilization 
of bone marrow granulocytes. In this in vivo test, granulocyte responses to etiocholanolone were found to 
be abnormal in 62% of SLE patients (85). There was no correlation between baseline granulocyte count 
and the magnitude of response to etiocholanolone. Most of the patients showing an abnormal response 
had normal bone marrow granulocyte reserve. However, the validity of this study has been challenged, as 
corticosteroids in dosages greater than 20mg of prednisone per day maximally challenge the bone marrow 
with regard to mobilization of granulocyte reserve (86). The average prednisone dose in the patients 
studied here was 34mg per day, which suggests that they were already maximally stimulated and would 
thus not be expected to show a normal granulocyte response to etiocholanolone. A further study also 
showed a depressed response to etiocholanolone in a patient, with improvement after azathioprine and/or 
prednisone (87). 
Drug induced granulocytopenia, for example due to phenylbutazone or azathioprine, should be home in 
mind, and other factors such as hypersplenism and infection may be contributory. 
Leucopenia · immune mechanisms 
Antibodies to granulocytes represent an important mechanism, with peripheral destruction of the 
antibody-coated cells. Patients with SLE have increased granulocyte-associated IgG, which results from 
binding of both circulating immune complexes and granulocyte autoantibodies. However, the level of 
granulocyte-associated IgG does not correlate with the granulocyte count (88). Of the many issues that 
remain unresolved, four are relevant. These are whether immune complexes alone cause 
granulocytopenia or whether granulocyte autoantibodies are also involved; why immune complexes might 
cause only granulocytopenia since there are many other target tissues, and why many patients with 
circulating immune complexes are not granulocytopenic. 
The problem of the relevance of granulocyte antibodies is further compounded by the multitude of tests 
available for measuring anti-neutrophil antibodies, which include granulocytotoxic assays, staphylococcal 
protein A (SPA) assays, leucoagglutination assays, antiglobulin immunofluorescence techniques, 
antiglobulin consumption assays, radio-labelled antiglobulin tests and solid-phase immunoassay 
(89,90,91,92,93,94). Differences in specificity and sensitivity make it difficult to compare results of the 
various tests. Furthermore, the presence of isoantibodies against leucocytes, which may be a consequence 
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of multiple pregnancies and/or blood transfusions, must be differentiated from true leucocyte 
autoantibodies in the interpretation of the results. 
Killman (95) performed leucocyte agglutination tests on patients with connective tissue diseases, and 
found that the prevalence of these agglutinins was higher in the SLE group than in the other connective 
tissue diseases. Two independent studies have demonstrated the high frequency of positive direct 
antiglobulin consumption tests on leucocytes in SLE (96,97) . Dausset et al reported positive results in 22 
of 24 SLE patients tested (96), while Engelfriet et al found 9 positives of 23 SLE patients. Circulating 
antibodies reactive with normal human leucocytes were detected with the indirect antiglobulin 
consumption test in over 90% of SLE patients (97). 
A simple in vitro approach to elucidating the cause of granulocytopenia in patients with SLE is not 
presently available (98). However, efforts to determine whether there is increased granulocyte-associated 
lgG are probably valuable because such patients are said to respond well to corticosteroids (99). 
Colony forming units in culture, or CFU-C, are haematopoietic colonies which are grown in vitro and 
represent committed stem cells. Addition of colony stimulating factors to the culture medium results in 
enhanced production of GM-CFUc's, which are colony forming unit-granulocyte macrophage. These 
then generate granulocytes and macrophages. 
Central bone marrow depression of granulocyte synthesis has been demonstrated using the 
colony-forming unit assay. Mouse bone marrow colony-forming units were incubated in the presence of 
human colony-stimulating factor as a model for in vivo human marrow production. Forty-three percent of 
SLE sera retarded bone marrow colony formation, whereas none of the control sera showed this effect. 
The degree of marrow colony retardation was directly correlated with amounts of test serum added (100). 
Further support for bone marrow depression of granulopoiesis in SLE patients was seen in a study of 16 
patients. Here the number of CFU-C in the bone marrow of these patients was significantly decreased in 
comparison with the control group, and furthermore these numbers correlated strongly with the 
peripheral granulocyte/monocyte counts. In addition, peripheral blood and bone marrow T-lymphocytes 
suppressed the colony formation of autologous or allogeneic bone marrow CFU-C, suggesting a 
suppressor role of T-lymphocytes on marrow CFU-C (101). Serum from a patient with SLE and aplastic 
anaemia was shown to contain an IgG complement-dependant antibody which suppressed CFU-GM 
growth from normal donor bone marrow. The antibody was removed by plasma exchange (102). 
Treatment 
Management of clinically significant granulocytopenia has conventionally relied on various forms of 
immunosuppression, including corticosteroids (99), and cyclophosphamide (31,32,99,103), with variable 
results. The role of haematopoietic growth factors has not yet been evaluated in this setting. 
Lymphocytopenia is common in SLE and is usually due to lymphocytotoxic antibodies. It will not be 
discussed further in the present study. 
Throntbocytopenia 
Thrombocytopenia, when defined as less than about 150x1091L, occurs in 7-41 % of patients with SLE 
(3,4,31,32,33,72,104,105) with a minority (5%) having thrombocytopenia of a severe degree. Purpuric 
lesions are the main manifestations of the low platelet counts. Thrombocytopenia of mild to moderate 
degree (50-100xl091L), often appears during exacerbations of the disease without any bleeding tendency 
(1). 
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Tbrombocytopenia . non-immune mechanisms 
Depression of thrombocyte production as shown by a markedly reduced number of megakaryocytes in the 
marrow is rare (106,107). 
Thrombocytopenia · immune mechanisms 
In contrast to the above, peripheral platelet destruction is an established mechanism and autoimmune 
thrombocytopenia can be a prodrome for SLE (108). Some patients with thrombocytopenic purpura 
labeled as idiopathic at the onset later develop a classical clinical co~se of SLE (109,110). Thus 
thrombocytopenia in SLE, as in chronic immune thrombocytopenic purpura (ITP), has been considered 
to be due to increased peripheral destruction of platelets brought about by autoimmune mechanisms. 
Platelet survival studies. in SLE with chromium 51-labeled platelets have demonstrated shortened life 
span (111). 
Many in vitro tests have been devised to demonstrate anti-platelet antibodies in SLE, but a test of 
universally accepted specificity, sensitivity and reproducibility is not available. Anti-platelet antibody 
assays which have been employed in SLE include platelet agglutination (112,113), direct antiglobulin 
consumption test (96,114), dextran agglutination test (115), platelet factor 3 method (116), and indirect 
immunofluorescence test (117,118). These tests are frequently positive in thrombocytopenic SLE 
patients, but have limited clinical application because of technical deficiencies. The latter include 
measurement of circulating immune complexes with the anti-platelet antibodies, as well as lack of 
sensitivity and specificity. Karpatkin et al (116) detected platelet antibodies in 78% of SLE patients, of 
whom only 14% were thrombocytopenic. 
Tests that measure platelet-associated IgG are widely used (119). Platelet-associated IgG has been 
measured and found to be increased in practically all SLE patients with thrombocytopenia 
(120,121,122,123,124). Kelton and co-workers (122) reported an inverse correlation between platelet 
count and platelet-associated IgG in 10 thrombocytopenic SLE patients. Mulshine et al (125) confirmed 
this inverse correlation, further observing that SLE patients with normal platelet counts had 
platelet-associated IgG even lower than that of normal controls. On the other hand, Bonacossa and 
associates (126) found elevated platelet-bound IgG in nonthrombocytopenic SLE patients, and this too 
has been supported by other workers (127). The IgG antiplatelet antibody in SLE involves all 4 subclasses 
of IgG (128). 
The nature of the platelet-associated IgG is not completely understood. It may represent IgG antibody 
bound to platelet specific antigens, known as autoantibodies, IgG antibody bound to Ill.A or blood group 
antigens or to exogenous antigens adsorbed on the surface of platelets, IgG non-specifically bound to 
damaged platelets, or circulating immune complexes bound to platelet surface Fe receptors (119,129). 
Kaplan et al (130) showed that three out of nine SLE patients with thrombocytopenia possessed a true 
autoantibody to platelet-specific antigens. 
In those patients with no detectable increase in platelet associated IgG and thrombocytopenia, cellular 
immune destruction may be causative, as in the case of idiopathic thrombocytopenic purpura without 
detectable surface antibody (131,132). 
An increase in bone marrow megakaryocyte numbers is paralleled by an increase in megathrombocytes, 
which are large platelets, in the peripheral blood (133). Two-thirds of non-thrombocytopenic patients 
with SLE were found to have an increased megathrombocyte count and number of megakaryocytes (133). 
Five of these eight patients studied had shortened platelet survival. This suggested the presence of a 
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compensated thrombocytolytic state, a theory supported by Karpatkin et al (1.34). These authors showed 
a similar increase in the percentage of megathrombocytes in non-thrombocytopenic patients with SLE, 
and detected platelet antibody in 85 per cent of SLE patients. 
Treatment 
Corticosteroid therapy in doses of 1.5mg/kg/day of prednisone equivalent is the treatment of choice for 
the autoimmune thrombocytopenia of SLE. Responses often occur only after 4-6 weeks. Steroid therapy 
failure occurs in 10-20% of these patients, who may require immunosuppressive agents or splenectomy 
(1). Azathioprine and cyclophosphamide are beneficial in thrombocytopenia associated with SLE 
(135,136,137). A 4-5 week therapeutic trial of the immunosuppressive agent is recommended before 
considering the thrombocytopenic patient a treatment failure (138). Vincristine may be of use in 
life-threatening thrombocytopenia unresponsive to other treatment mobilities (139). Danazol 
(140,141,142) and high-dose intravenous gammaglobulin (143) have also been used for refractory disease. 
Plasma exchange is reserved for life-threatening situations (28). 
OfflER ABNORMALITIES 
A number of other haematological problems, mainly of the coagulation system, may occur in SLE 
patients. 
Mild qualitative platelet defects, which are usually not associated with significant bleeding problems, are 
sometimes found (144). 
Patients may rarely develop antibodies to certain haemostatic factors, including the Von Willebrand 
factor and factors VIII, IX, and XI, with resultant haemorrhage (1). 
The lupus anticoagulant is an immunoglobulin reacting with procoagulant phospholipids occurring in 
approximately 10 percent of SLE patients. It is thought to act by inhibiting the activation of prothrombin 
by prothrombinase. Clinical associations include venous and arterial thrombosis and recurrent 
spontaneous abortions, but not haemorrhage. A subset of patients with the lupus anticoagulant have 
hypoprothrombinaemia, and they may suffer from severe bleeding (1). 
In summary, cytopenias appear to be common findings in SLE patients. However, the mechanisms 
responsible are not well defined. This study was thus undertaken to document the incidences of the 
individual cytopenias in our local SLE patient population, as well as to attempt to contribute to the 
understanding of underlying mechanisms. This information could aid in future therapeutic decisions. 
CHAPTER THREE 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
PATIENT SELECTION 
Seventy patients fulfilling the presently accepted criteria for the diagnosis of systemic lupus 
erythematosus (4) were studied (Table 2.1). Except for two patients who were hospitalized with newly 
diagnosed lupus, the remainder were clinically stable and attended the Groote Schuur Hospital Lupus 
outpatients clinic. None of the patients were receiving steroid or immunosuppressive therapy at the time 
of the study, and splenectomized subjects were excluded. Clinical status, lupus serology and therapy was 
documented. Bone marrow studies were conducted on sixteen patients, six of whom belonged to the 
original group of seventy, the remainder being SLE patients who required this procedure for therapeutic 
reasons. The marrow examinations in the former six subjects were all performed at a later stage than the 
peripheral blood studies. 
LABORATORY PROCEDURES 
PERIPHERAL BLOOD 
These specimens were obtained from all the seventy patients on a single occasion after an overnight fast 
and the following investigations performed: 
• A full blood count (FBC) on the Coulter S Plus 11. 
• Reticulocyte count, expressed as a percentage with correction for red cell count (145). 
• Monospecific direct Coombs' test, utilizing specific anti-IgG and anti-complement antisera (145). 
• Serum iron, percentage saturation, total iron binding capacity (TIBC) and serum ferritin by 
radioimmunoassay (145). 
• Serum and red cell folate and serum vitamin B12 levels by radioimmunoassay (145). 
• Measurement of serum anti-neutrophil antibody levels were kindly performed by the laboratory of 
Professor J.P. Crowley, of Rhode Island Hospital, Providence. A cellular enzyme linked 
immunosorbent assay (CELISA) technique was employed, and the assay was performed twice on each 
patient, utilizing normal human polymorphonuclear neutrophils (PMN's) and an HL-60 line as target 
cells respectively (146). Briefly, the assay features a solid phase microtitre method in which the enzyme 
urease is fixed to the antihuman globulin conjugate reagent and uses either PMN's or HL-60 line cells 
as targets. The assay detects autoimmune and isoimmune antineutrophil antibodies and IgG containing 
circulating immune complexes. An attempt was made to establish this assay in our laboratory, based on 
the method of Crowley et al (146). This proved unsuccessful, however, due to failure to obtain 
significantly different absorbance readings between heated (positive control) serum and unheated 
(negative control) serum. This problem remains unsolved at the present time. 
• Platelet-associated immunoglobulin levels were quantitated by direct ELISA technique, using a 
modification of the method of Nel and Stevens (147). The assay measures platelet-associated IgG by 
measuring the competition for binding of anti-IgG between the platelet-associated IgG and IgG on the 
surface of the wells on microtitre plates. Polyvinyl microtitre plates (Nunc Immunoplate Cat. No. 
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439454) are coated with IgG from pooled human sera. Platelets are prepared from 10-15mls 
EDTA-anticoagulated blood by differential centrifugation, and the count is adjusted to 50xl09/L. The 
platelets are then incubated in the microtitre wells, together with antihuman IgG which is conjugated 
to horseradish peroxidase enzyme (Daleo Code No. P214). The anti-human IgG binds to lg on the wells 
and to IgG on the platelet surface, if this is present. The greater the amount of antiglobulin consumed 
by the reaction with platelets, the less is available to bind to the immune adsorbent in the microtitre 
well. Platelets are then washed out of the wells and the unbound fraction of antiserum is quantitated by 
allowing it to react with a chromogenic substrate (o-phenylenediamine/hydrogen peroxide) for the 
enzyme and measuring the intensity spectrophotometrically. The colour produced is inversely 
proportional to the amount of platelet membrane-bound IgG. This is calculated by subtraction and 
expressed as a percentage binding. A series of standards of IgG (Behring Code No. ORDT 06/07) 
ranging from 25-800ng IgG are assayed simultaneously, and the amount of platelet-associated IgG is 
obtained from the sigmoid-shaped standard curve using the calculated percentage binding. Platelets 
from normal donors gave values of 10-lOOng IgG/107 platelets. 
BONE MARROW· MORPHOLOGY 
Sixteen SLE patients, of whom six belonged to the original group of seventy who had earlier had 
peripheral blood studies, required bone marrow aspiration and trephine biopsy in the course of their 
disease. At the time of marrow sampling, seven were receiving steroid and/or immunosuppressive 
( cyclophosphamide) therapy. 
The marrow samples were obtained from the posterior iliac crest and were prepared and stained in the 
usual manner. They were examined morphologically to assess cellularity and the individual cell lines. Iron 
status and megaloblastic features were noted and the anatomy of the blood vessels examined. 
BONE MARROW· IN VITRO CULTURE. 
In vitro bone marrow culture studies were performed on 10 of the patients (five of the peripheral blood 
study group), from whom sufficient marrow aspirate could be obtained, as follows: 
Erythroid Colony Culture 
10 ml of bone marrow aspirate and 10 ml of clotted blood was obtained from each patient and processed 
according to a modified method of Iscove (148) and Johnson (149). The aspirate was collected into 0.3ml 
preservative free heparin (Pularin), diluted 1:3 in 20% AB serum in McCoy's tissue culture medium 
(Gibco Cat. No. 074-1550) and separated on Ficoll Hypaque (1.077g/ml). The mononuclear cells were 
washed in 20% serum in McCoy's tissue culture medium, and 2.0xlcfcells/ml were added to wells of 
tissue culture plates. 0.5ml of the respective serum type - AB, patient's serum (room temperature), and 
patient's serum (heat inactivated at 56° C for 15 minutes) was added to each of three tubes, together with 
0.125ml erythropoietin (Connaught) of 0.25units/ml final concentration for CFU-E and 2.0units/ml final 
concentration for BFU-E, 2-mercapto-ethanol (Merck), with a final concentration of 104 , 0.125ml 
asparagine of 0.02g/ml final concentration, the appropriate volume of cells, which were equal to 
2.0xla5cells/ml, and agar (Difeo Bacto-agar 0140-01) at a final concentration of 0.3%. The mixtures were 
then plated into wells of a culture dish. The plates were incubated in humidified 5% CO2 at 37' C for 7 
days (CFU-E) and 14 days (immature BFU-E). Agar gels were harvested by fixing with formal acetone 
buffer, washed with distilled water, allowed to dry on microscopy slides and stained with 
haematoxylin-tetra-aminobiphenyl hydrochloride (BDH). The number of CFU-E, defined as fewer than 
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32 and 32-64 cells per group, and BFU-E, greater than 64 cells per group, were recorded for each of the 
three different serum groups. The numbers obtained in the control (AB) serum group were compared 
with those in the patient groups (plain and decomplemented serum). 
Granulocyte:Macrophage Colony (GM-CFUc) Culture 
10ml of bone marrow aspirate was obtained per patient and processed by a technique adapted from a 
micro agar culture method for cloning erythropoietic progenitors (150). The aspirate was collected into 
0.3ml of preservative free heparin (Pularin), diluted 1:1 with 20% AB serum in McCoy's tissue culture 
medium (Gibco Cat. No. 074-1550), and separated on Ficoll Hypaque (1.077glml). The mononuclear 
cells were washed in McCoy's tissue culture medium. A suspension of mononuclear cells at a 
concentration of 2.0xla5cells/ml was made in McCoy's tissue culture medium with each of 15% foetal calf 
serum (FCS) (State Health Laboratories), patient's serum and patient's serum heated to 56° C for 15 
minutes. The final concentration of agar (Difeo Bacto-agar 0140-01) added was 03%. 0.25ml of this 
suspension was pipetted into multiwell tissue culture plates. An overlayer of 0.25ml of colony stimulating 
activity (CSA), derived from leucocyte conditioned medium, (CSA-LCM) diluted in the appropriate 
serum was added to the wells. A control well overlayered with the appropriate 15% serum in McCoy's 
tissue culture medium without CSA was set up for each patient. The plates were incubated in 5%C02 at 
37°C for 7 and 12 days respectively. Agar gels were harvested by fixing with 2.5% glutaraldehyde, washed 
with distilled water, allowed to dry on microscope slides and stained with a Romanovsky stain 
(May-Grunwald-Giemsa). The number of colonies, defined as a group of more than 40 cells, and clusters, 
a group of 4-40 cells, was recorded for each of the three serum groups. The numbers obtained in the 
control (FCS) group were contrasted with the patient groups (plain and decomplemented serum). 
STATISTICAL ANALYSIS. 
Correlations were analyzed by linear regression and determination of correlation coefficients. Differences 
between the mean values in the in vitro bone marrow culture studies were evaluated using the Student's 
t test. 
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RESULTS 
Seventy patients had peripheral blood studies over a period spanning 20 months. In the same period, 
sixteen bone marrow examinations were performed. Of these, six were done on the original peripheral 
blood group, all at a time subsequent to the blood studies. The remaining ten marrows were from other 
SLE patients. 
PATIENT DATA 
In the group who had peripheral blood studied, the age of the patients ranged from 15 to 65 years with a 
mean of 39 years. There were 5 males and 65 females. There was a predominance of mixed ancestry 
(Coloured) (151) patients in this study, which reflects the true incidence as seen in the Western Cape. 
The sex and race distribution is shown in Figure 4.1. 
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Pig. 4.1 Race and sex distribution of SLE patient population. (C = coloured (mixed 
ancestoi:y); B=black; W=white; M=male; F=female). 
The mean duration of diagnosed SLE at the time of the study was 4.3 years, ranging from newly 
diagnosed patients, of which there were two, to 18 years. 
Thirty-six of the seventy patients were assessed as having active disease on the basis of clinical and/or 
serological findings. Serological tests were not undertaken on those patients thought to have only mildly 
active or inactive lupus. Besides two newly diagnosed patients, the remainder were chronic and clinically 
stable, being regularly seen at the Lupus outpatients clinic. Three patients had chronic renal failure. None 
were taking steroid or immunosuppressive medication at the time of study, and splenectomized subjects 
were excluded. Patient profiles are given in the Appendix. Subjects having bone marrow studies all had 
active disease, based on the above criteria. They included seven on steroid and/or immunosuppressive 
therapy and three with chronic renal failure. 
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LABORATORY DATA 
CYTOPENIAS 
In the peripheral blood study group, a total of 29 patients exhibited cytopenia(s) of one or more cell lines. 
Nineteen patients were anaemic, nine were both anaemic and leucopenic, and only a single patient was 
pancytopenic, defined as haemoglobin less than 110g/L, white cell count below 4x109 /L, and platelets 
below 100x109 /L. This is diagrammatically represented in Figure 4.2. 
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Fig. 4.2 Frequency of the cytopenias (n = 29) 
The mean haemoglobin value was 113 !efl,, with a range of 63-169 (males) and 60-152 (females). 
Twenty-nine patients (41%) were anaemic, with a haemoglobin level below 110 !efl,. The majority of 
these, 12 (17%), were shown on iron studies to have an anaemia of chronic disease. They were closely 
followed by 10(14%) patients with iron deficiency. Two patients were folate deficient, one was Vitamin 
B12 deficient, and the remaining four had anaemias which could not be characterized. All three chronic 
renal failure patients were anaemic (range 63-108!efl,). One belonged to the chronic disorders anaemia 
group, one was iron deficient, and one was in the non-characterized group. These features are shown in 
the diagram in Figure 4.3. 
Coombs' test was positive in 17 (24%) patients. The specificity was as follows: lgG positive - 11, 
complement positive - 4, and both IgG and complement positive - 2 patients. This is diagrammatically 
represented in Figure 4.4. None of these patients exhibited haemolytic anaemia ( defined here as anaemia 
and Coombs' positivity with raised reticulocyte count in the presence of normal iron, folate and vitamin 
B12 status) at the time of the study; however, four had either had an autoimmune haemolytic anaemia 
previously or were observed to develop this complication with time. There was no correlation between 
anaemia and Coombs' positivity .. 
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Fig. 4.3 Characterisation of anaemia (n = 29). (ACD = anaemia of chronic disease; FE 
DEF= iron deficiency; PO LATE DEF= folate deficiency; B12 DEF= vitamin B12 
deficiency.) 
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Fig. 4.4 Specificity of Coombs' positivity (n = 17). (C' =complement.) 
In vitro erythroid bone marrow cultures 
29 
In vitro erythroid bone marrow cultures were performed in 10 patients. Table 4.1 shows the results 
obtained. At the time of sampling, nine of the ten patients were anaemic, with haemoglobin levels 
between 36-108 g/L and seven were receiving steroid therapy, one of whom was also on 
cyclophosphamide. Four patients had raised anti-DNA titers. There was no significant difference in 
BFU-E or CFU-E growth on addition of autologous serum (plain or decomplemented) to the patient's 
marrow, compared to control serum. Plate 4.1 illustrates the in vitro BFU-E growth in one of the patients' 
bone marrow on addition of autologous serum at room temperature to the cultures. 
Results 
Table 4.1. In vitro crythroid bone marrow cultures. 
BFU-E 
control (AB serum) 
autologous serum 
control (AB scrum) 
autologous serum 56°C 
CFU-E 
control (AB scrum) 
autologous scrum 
control (AB serum) 
autologous scrum 56°C 
NS = not significant 
LEUCOPENIA 
Peripheral Blood Data. 
colonics/2xlo5 cells 
32±n 
2±5 
32±n 
26±63 
colonics/2xlo5 cells 
349±326 
291±167 
349±326 
318±121 
30 
pvaluc 
NS 
NS 
pvaluc 
NS 
NS 
The mean white cell count was 5.7x109(L, with a range of 2.4-11x109(L. Sixteen patients (23%) were 
leucopenic with a white cell count below 4x109 /L and 8 (11 % ) were absolutely neutropenic, defined as a 
neutrophil count less than 2.0x109 /L. Lymphopenia, with an absolute count less than 1.Sx.109 /L, was 
present in 34( 49%) subjects. 
Assay of anti-neutrophil antibody activity showed 41 (59%) positivity in the CELISA assay with HL-60 
cells, 6 (9%) positive with the normal human polymorphonuclear neutrophils (PMN's) and 4 (6%) 
positive with both assays. These results are shown in Figure 45. 
No correlation existed between absolute neutrophil count and anti-neutrophil antibody level with either 
of the assays (HL-60: p=0.69, r=-0.048; PMN's: p=0.02, r=0.27). 
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Fig. 4.5 Anti-ncutrophil antibody positivity by CEI.lSA assay 
(PMN = polymorphonuclcar ncutrophils ). 
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In vitro GM-CFUc bone marrow cultures 
In vitro GM-CFUc bone marrow cultures were performed on 10 patients. The results are shown in Table 
4.2. At the time of sampling, only one patient was leucopenic, and none were absolutely neutropenic. 
Seven were receiving steroid therapy, two of whom were also on cyclophosphamide. Four patients had 
raised anti-DNA titers. Both on days 7 and 12 addition of autologous serum (plain or decomplemented) 
to the patient's marrow gave rise to significantly enhanced GM-CFUc growth. However, as the control 
serum here was foetal calf and not normal human serum, the difference in growth may be accounted for 
by this species difference, with possible inhibition of growth occurring with the foetal calf serum. Plate 4.2 
illustrates the comparison of GM-CFUc growth in one patient on day 7 with addition to the cultures of 
control versus autologous serum. 
Table 4.2. In vitro GM-CFUc bone marrow cultures. 
Day7 
control (PCS) 
autologous serum 
control (PCS) 
autologous serum 5tf'C 
Day12 
control (PCS) 
autologous serum 
control (PCS) 
autologous serum 5ff'c 
colonies/2xlif cells 
173±118 
237±138 
173± 118 
213±125 
colonies/2xlif cells 
64±51 
133±81 
64±51 
113±72 
pvalue 
p<0.05 
(CL64±50) 
p<0.05 
(CL40±32) 
pvalue 
p<0.05 
(CL69±56) 
p<0.05 
(CL49±46) 
PCS = foetal calf serum. CL represents confidence limits at 95% level. 
THROMBOCYTOPENIA 
The mean platelet count of the seventy patients was 267x109 /L, with a range of 88-593xllf /L. Only 2 
patients (3%) were thrombocytopenic, with a platelet count below 100x109 /L, 
Platelet associated immunoglobulin levels were raised in 21 (30%) patients, with values ranging from 
110-1143ng IgG/107 platelets. However, there was no correlation between platelet count and platelet 
antibody level (p=0.099, r=-0.199). Furthermore, no correlation existed between platelet count and 
mean platelet volume (MPV) (p = 0.058, r = -0.28). 
BONE MARROW FINDINGS. 
Sixteen bone marrow samples were examined by aspiration and trephine biopsy. Fifteen patients were 
anaemic at the time of sampling, with haemoglobin ranging from 36-108g/L, mean 78g/L; five were 
leucopenic with white cell counts ranging from 1.3-3.9x1.09 /Land a mean of 3x1.09 /L, and four had platelet 
counts below 100x109 /L, ranging from 36-88x1.09 /L, with a mean of 63x1.09 /L. Seven subjects were 
receiving steroid and/or immunosuppressive (cyclophosphamide) therapy. 
Results 32 
The bone marrow was assessed as normocellular in 5 patients, mild to moderately hypocellular in 7 and 
slightly hypercellular in 4. Erythroid line was deficient in 5 patients with 2 patients having mild 
granulocytic hyperplasia. Megakaryocytes were prominent in 3 cases. Iron stains revealed 8 subjects with 
an anaemia of chronic disease, while 3 were absolutely iron deficient. There was evidence of 
megaloblastosis in 5 patients. Features of renal osteodystrophy were seen in 3 specimens, while none of 
the biopsies revealed evidence of vasculitis. 
IMMUNOLOGICAL DATA 
A positive correlation existed between anti-neutrophil antibody level with Ill.,-60 cells and anti-platelet 
antibody level (p.05, r = 0.31), but not with the PMN assay (p = 0.05, r = 0.23). 
Attempts to show a correlation between either haemoglobin, white cell count or platelet count and 
anti-DNA level as a marker of disease activity were negative. Values obtained for p and r were: 
haemoglobin: p = 0.027, r = -0.28; white cell count: p = 0.05, r = -0.25; platelet count: p = 0.42, r = 0.104. 
Consideration of subjects with antibody titers raised against the respective haematological cells revealed 
that 8 were both Coombs' positive and anti-neutrophil antibody positive (by either assay); 3 were 
Coombs' positive and platelet antibody positive; 16 had antibodies to both neutrophils and platelets, and 
3 patients were positive for all 3 antibody types. Of 21 subjects having one or more of these antibodies, 9 
had anti-DNA titers above the normal range. None of the 3 patients having antibodies against all cells had 
raised anti-DNA levels. These figures are summarized in Table 4.3. 
Table 4.3. Immunological data. 
Test 
Coombs'· NAb 
Coombs'; Pit Ab 
NAb; Pit Ab 
Coombs'; NAb; Pit Ab 
Anti-DNA Ab 
NAb = anti-neutrophil antibody 
Pit Ab = platelet antibody 
Number Positive 
8 
3 
16 (positive correlation) 
3 
9/21 
Results 
Plate 4.1. In vitro BFU-E in an SLE patient on addition of autologous serum at room 
temperature. 
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(a) 
(b) 
Plate 4.2 In vitro GM-CFUc on day 7 showing colonies and clusters on addition of control serum (a) and autologous serum (b ). 
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DISCUSSION 
Systemic lupus erythematosus (SLE) is a multisystem disease characterized by the production of 
pathogenic autoantibodies and immune complexes causing tissue and cellular damage. 
One of the main targets is the haematologic system, and the majority of SLE patients will demonstrate 
some abnormality involving it during the course of their disease. 
This study has focused on the cytopenias encountered in SLE patients. In order to minimize the effects of 
drugs on haematological parameters, subjects were chosen who had either never been exposed to, or 
were not taking, steroids or immunosuppressive agents at the time of the study. Of seventy patients 
studied, thirty-six had active disease. However, except for two subjects who were hospitalized with newly 
diagnosed lupus, the remainder were chronic sufferers, being followed as outpatients. 
Although SLE is characterized by recurrent exacerbations and remissions which may also be reflected in 
changing haematological status, patients were studied at a single time point. This enables one to establish 
a baseline measure of haematological function, upon which further fluctuations may be observed to be 
superimposed. 
A number of studies have been conducted on large groups of SLE patients, in which the incidences of the 
cytopenias have been documented (31,32,33,34). However, these figures include patients at different 
stages of the disease, as well as those taking steroids and/or immunosuppressives. These factors may have 
a substantial effect on the figures obtained. 
Elucidation of the mechanisms responsible for the cytopenias has been bedevilled by the very nature of 
SLE, being regarded as an autoimmune disease of unknown aetiology, together with the presence of 
various complicating factors, for example infection, drug therapy and concomitant renal failure. At 
present these mechanisms remain largely undefined, despite a large body of studies, many of which are of 
an immunological nature. 
This study has documented the incidence of the individual cytopenias in 70 selected SLE patients and has 
attempted to define the mechanisms underlying these abnormalities. 
ANAEMIA 
The incidence of anaemia, defined as a haemoglobin of less than llOg/L, was 41 % in this series, which is 
in keeping with the reported range of 38-98% (31,32,33,34). Consistent with previous studies (35), the 
majority of these patients (17%) had an anaemia of chronic disease. Fourteen percent of patients were 
anaemic on the basis of iron deficiency. Although this may be due to occult gastrointestinal blood loss 
(35) presumably on the basis of vasculitis or anti-inflammatory or steroid drug ingestion, the majority of 
the patients were females of childbearing age, in whom iron deficiency may be a common occurrence. 
The reason for folate deficiency in 2 patients, and vitamin Bl2 deficiency in 1 patient, may not be 
specifically related to SLE, and 4 subjects were anaemic due to an undetermined cause. Chronic renal 
failure was contributory in three cases. 
Bone marrow examination was helpful in showing an anaemia of chronic disease in eight of sixteen 
patients studied, and also demonstrated mild to moderate erythroid hypoplasia in five, some of the latter 
possibly being on the basis of renal failure. None of the patients had red cell aplasia. 
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Coombs' positivity in 17(24%) of patients is consistent with the reported incidence of 18-65% 
(32,61,63,64). However, the pattern of Coombs' positivity here was most frequently IgG alone in 11 
patients, with complement alone in 4, and both IgG and complement being positive in only 2 patients. 
This is at variance with other series, in which Type II, where both immunoglobulin and complement are 
found, or Type ill reactions, with complement alone, are most frequently encountered (65,66,67). The 
reason for this difference in pattern of reactivity is not immediately obvious. Although none of the 
patients had autoimmune haemolytic anaemia at the time of study, four previously had, or subsequently 
developed, this complication in the course of their disease. 
Erythroid cultures (CFU-E and BFU-E) were performed on 10 patients, but failed to show an inhibitory 
influence of autologous serum ( either plain or decomplemented) on erythroid colony growth compared 
to control serum. Although CFU-E and BFU-E growth was decreased on addition of autologous serum 
(both plain and decomplemented) compared to control serum, these differences were not statistically 
significant. Although 9 of the patients were anaemic, the majority were on steroid therapy, which may 
conceivably mask serum immune activity. Furthermore, the numbers studied here were small and studies 
of larger groups of patients are necessary before definitive statements can be made. These patients should 
preferably not be receiving any form of immunosuppressive therapy. 
A number of in vitro studies have demonstrated humoral inhibition of erythropoiesis in SLE patients. 
Yamasaki et al (78) demonstrated a decreased incidence of CFU-E in 9 SLE patients, and further 
showed that addition of allogeneic and autologous T-lymphocytes from SLE patients not receiving 
corticosteroid therapy suppressed CFU-E colony formation. Dainiak et al (76) demonstrated inhibitory 
activity in sera from 7 anaemic patients on both autologous and allogeneic BFU-E and CFU-E growth, 
and this was abolished with steroids and plasma exchange. Five cases of serum suppression of CFU-E 
growth in normal human bone marrow were described by Kallen et al (75), all of whom responded to 
steroids. Red cell hypoplasia in an SLE patient was shown to be associated with inhibition of erythroid 
colony growth by the IgG fraction of the patient's serum, suggesting the presence of an autoantibody to 
erythroid precursors (74). The serum of an SLE patient with aplastic anaemia was shown to contain a 
complement-dependant lgG antibody that inhibited erythroid and granulocytic colony formation of 
normal human bone marrow (79). This improved after plasma exchange with haematologic recovery. 
Meyer et al (77) demonstrated a serum inhibitor of erythropoiesis in an SLE patient with autoimmune 
haemolytic anaemia and periodic episodes of red cell hypoplasia. 
The results of these studies suggest that humoral inhibition of erythropoiesis may be operative in a subset 
of patients, but demonstration that this is a widespread phenomenon in the pathogenesis of anaemia 
awaits larger scale in vitro bone marrow culture studies. 
LEUCOPENIA 
A white count below 4x109 /L was found in 23% of patients. This is somewhat lower than the reported 
incidence of 35-80% (4,31,33,34). The observed difference may be due to the fact that almost half of the 
patients in this study had inactive disease. 
The present study was concerned with granulocytopenia, although it is recognized that lymphocytopenia 
is a common occurrence in SLE. Eight (11 % ) patients were absolutely neutropenic. 
The mechanisms underlying granulocytopenia in SLE are complex, and despite extensive investigations, 
few firm conclusions have been made. Contributing factors include impaired bone marrow mobilization 
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of granulocyte reserves (85,86,87); peripheral immune-mediated granulocyte destruction (98); and central 
marrow suppression of granulocyte synthesis (100,101,102). In some cases multiple mechanisms may be 
operative. 
None of the bone marrows examined demonstrated granulocyte hypoproduction. 
Studies assessing mobilization of marrow granulocyte reserves were not undertaken. 
The difficulties in interpreting results of anti-neutrophil antibody assays have been discussed above. 
These include elucidation of the relative roles of granulocyte autoantibodies and immune complexes in 
the granulocytopenia, and evaluation of multiple different assays with varying sensitivities and 
specificities. 
However, a number of studies have demonstrated the presence of anti-neutrophil antibodies in SLE 
patients (88,95,96,97,99), although the level of granulocyte-associated IgG does not correlate with the 
granulocyte count (88). 
In the present study an ELISA assay utilizing both HL-60 cells and human polymorphonuclear 
neutrophils (PMN's) was employed for measuring serum anti-neutrophil antibody levels. Assay with the 
HL-60 cells was shown to be more sensitive, being positive in 41 (59%) patients, with 9% positivity with 
PMN's. No correlation existed between the antibody level and the absolute granulocyte count. Thus 
although direct comparisons are not possible between these and other assay results, 
granulocyte-associated immunoglobulin probably does play a role in peripheral destruction of these cells; 
however the magnitude of its contribution to granulocytopenia has not been determined. Demonstration 
of an anti-neutrophil antibody in a granulocytopenic patient may be still be useful, in that such a patient 
may be expected to respond to steroid or other immunosuppressive therapy. 
In vitro GM-CFUc studies conducted in 10 patients showed a significant enhancement of colony growth 
when autologous serum (plain or decomplemented) was added to bone marrow compared to control 
serum. While the possibility exists that this difference may be due to growth inhibition by foetal calf serum 
in the control cultures, these results would appear to be in direct contradiction to previous studies, in 
which inhibition of CFU-C growth on addition of sera was demonstrated in SLE patients, not all of whom 
were neutropenic (100,101,102). However, these may not be directly comparable due to fundamental 
differences in study design. One study used mouse bone marrow cells and patient's serum compared to 
control serum (100), the other reported the effect of patient's peripheral blood and marrow 
T-lymphocytes on CFU-C's (101), and the third detailed the effect of disease-phase versus 
remission-phase serum on normal marrow CFU-GM in one patient (102). In the present study, only a 
single patient was leucopenic and none of the 10 were absolutely neutropenic. It is conceivable that these 
sera contained stimulatory growth factors which enhanced central granulocyte synthesis and whose 
absence may contribute to granulocytopenia. This hypothesis requires confirmation with investigation of 
larger groups of both neutropenic and non-neutropenic patients. Furthermore, most of the patients 
studied here were receiving immunosuppressive therapy (mainly corticosteroids), which may also modify 
immune function at the central level. 
Thus although the present study has failed to add support for a role of direct humoral inhibition of 
central granulocyte synthesis, it has raised the possibility of a role for stimulatory factors in the 
pathogenesis of granulocytopenia in a subset of patients. 
Discussion 39 
THROMBOCITOPENIA 
Only 2(3%) patients in this study had platelet counts below 1CX)x109 /L, while the numbers reported below 
150x109/L range from 7-41% (3,4,31,32,33,72,104,105). However, only about 5% are reportedly severely 
thrombocytopenic with counts below 50x109 /L. Once again, the fact that almost half the patients studied 
here had inactive disease may have been contributory. Some of the subjects were in fact observed to 
decrease their platelet counts at a later stage. 
Megakaryocyte hypoplasia was not demonstrated in any of the bone marrows. 
Peripheral immune destruction of platelets secondary to deposition of autoantibodies and/or immune 
complexes remains the most likely mechanism of thrombocytopenia in these patients. 
Platelet-associated immunoglobulin levels were increased in 21(30%) patients by direct ELISA technique 
in this study; however no correlation was shown between platelet count and platelet antibody level. Many 
studies have demonstrated frequent anti-platelet antibody positivity m SLE patients 
(120,121,122,123,124). Kelton et al (122) and Mulshine et al (125) demonstrated an inverse correlation 
between platelet count and platelet-associated IgG in thrombocytopenic SLE patients; however, 
Bonacossa et al (126) and Karpatkin et al (127) found elevated platelet-bound IgG in 
nonthrombocytopenic SLE patients. Thus a uniform set of conditions with respect to platelet count and 
platelet antibody does not appear to exist. 
Some investigators favour the presence of a compensated thrombocytolytic state in SLE (127,133,134). 
The present study did not show any correlation between platelet count and mean platelet volume to 
support this theory. In addition, two of the three patients with megakaryocytic hyperplasia were 
thrombocytopenic, suggesting peripheral platelet consumption. 
IMMUNOLOGICAL DATA 
A number of patients were found to exhibit immunological activity against one or more circulating 
haematological cells, demonstrated by 16 patients with both anti-neutrophil and anti-platelet antibodies, 8 
with Coombs' and anti-neutrophil antibody positivity, 3 with Coombs' and anti-platelet antibody positivity, 
and 3 had antibodies to all the cell types. However, none of the latter 3 patients had raised anti-DNA 
titers, and only 9 out of 21 subjects in the antibody positive groups were anti-DNA positive. Bearing in 
mind that about half of the patients had active but stable disease at the time of study, very few appeared 
to have broad range immunological activity against many different target cells or cellular constituents. 
This may be more convincingly shown in patients with more florid disease. Interestingly, a positive 
correlation existed between antibody levels against platelets and neutrophils (by the more sensitive HL-60 
assay). This possibly suggests a tendency for patients to simultaneously form antibodies to more than one 
cell type, demonstrating enhanced immune reactivity. 
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TREATMENT 
Management of cytopenic SLE patients is difficult and documentation of their incidence, and a clearer 
understanding of their pathogenesis, would aid in future therapeutic decisions. 
Based on studies thus far, immunosuppressive drugs, by damping down immune responses, and 
splenectomy, by removing the organ responsible for sequestering antibody-coated cells, would appear to 
be the most logical modalities of treatment. 
Anaemia, with chronic disease being the commonest cause, would benefit from treatment of the 
underlying condition, initially with steroids, followed by immunosuppressive agents in more severe cases. 
The value of employing recombinant erythropoietin in this setting remains to be established. Careful 
documentation of iron deficiency would precede appropriate replacement therapy. Autoimmune 
haemolytic anaemia refractory to steroids may require splenectomy or immunosuppressive drugs, namely 
cyclophosphamide or azathioprine. The role of Cyclosporin A is still being evaluated. Clinically 
significant granulocytopenia may benefit from a trial of cyclophosphamide, while haematopoietic growth 
factors and Cyclosporin A could be future options. Some cases of immune mediated thrombocytopenia, if 
unresponsive to corticosteroids, may respond to splenectomy, immunosuppressives being reserved for 
refractory patients. Once again, Cyclosporin A may in future prove to be of value in this setting. 
In summary, this study has confirmed the high prevalence of cytopenias in our select group of SLE 
patients, with anaemia being the commonest abnormality, followed by neutropenia and 
thrombocytopenia. Most patients had chronic disease anaemia; iron deficiency was also relatively 
frequent. Autoimmune haemolytic anaemia was not a feature of our patient group. Chronic renal failure 
contributed to anaemia in three cases. Humoral inhibition of erythropoiesis was not demonstrated. 
Peripheral immune granulocyte destruction was presumably the main mechanism underlying the 
observed neutropenia. The possibility of absence of stimulatory growth factors in the pathogenesis of 
neutopenia was suggested. Thrombocytopenia, which was observed in two patients, was thought to be on 
the basis of peripheral platelet destruction, with many more non-thrombocytopenic subjects having 
elevated levels of platelet-associated immunoglobulin. 
CHAPTER SIX 
CONCLUSIONS 
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CONCLUSIONS 
This study has confirmed the frequent occurrence of cytopenias in patients with systemic lupus 
erythematosus. Precise definition of underlying mechanisms is still not possible, but we have added 
support to that thought to account for the majority of cases of anaemia, namely chronic disease. Immune 
mediated destruction of granulocytes and platelets is the most likely cause of granulocytopenia and 
thrombocytopenia, although this could not be conclusively shown here. Documentation of these 
mechanisms is important to guide therapeutic decisions, as management is complex and at present relies 
mainly on the use of potentially harmful drugs. Future efforts should be directed at greater understanding 
of haematopoietic changes that occur in chronic disease, as well as standardization of immune-based 
assays to improve detection of peripheral destructive mechanisms. 
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APPENDIX: PATIENT PROFILES 
Appendix 
W = White 
C = Coloured (mixed ancestry) 
B = Black 
M = Male 
F = Female 
Hb = haemoglobin (g/L) 
Wee = white cell count (x109/L) 
Platelets = platelet count (xl.09 /L) 
KEY 
NSAIDS = non-steroidal anti-inflammatory drugs 
AM = anti-malarial drugs 
Abnormal lupus serology: N/D = not done 
Disease status: A = active; I = inactive; new = newly diagnosed 
AIHA = auto-immune haemolytic anaemia; CRF = chronic renal failure. 
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